Loading…
Also known as Cannabinol
Mildly psychoactive cannabinoid formed as THC oxidises and degrades over time, most concentrated in aged cannabis; marketed for sedative effects, though robust clinical trial evidence for sleep is still lacking.
We link to relevant studies and leave interpretation to you and your healthcare professional.
Where people report using it and what trials suggest
Common claims the trials do not support
Cannabinol marketed as 'the sleepy cannabinoid' on the back of stale 1970s combination studies — modern sedation evidence does not exist.
Safety notes: Mild psychoactivity at very high doses possible; otherwise little known.
Evidence grades reflect study quality and consistency, not marketing claims.
Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
In the UK, CBD products fall under the FSA novel foods list — buy from retailers listing an FSA-assessed product.